Literature DB >> 12464155

Treatment targeted to cell surface epitopes.

U Mrowietz1.   

Abstract

Expression of a variety of surface epitopes is a characteristic feature of immune cells. Receptors and adhesion molecules are the most predominant ones. It is also characteristic that epitope expression is modulated during cellular activation. In inflammatory skin diseases these structures can be used to define not only the type of cell but also their activity status. The availability of monoclonal antibodies and fusion proteins enabled to target cellular surface epitopes in order to modulate the cellular function as a principle of treatment. In psoriasis receptor-targeted therapy has been developed and tested in a considerable number of clinical trials. However, these approaches revealed that not all the strategies are equally effective. In this review the development of receptor-targeted treatment for skin disorders, mainly psoriasis, is described. Clinical as well as experimental data obtained with the various compounds employed are discussed with regard to clinical efficacy, safety and tolerability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464155     DOI: 10.1046/j.1365-2230.2002.01171.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  9 in total

1.  [Psoriasis therapy with biologicals].

Authors:  U Mrowietz
Journal:  Hautarzt       Date:  2003-02-11       Impact factor: 0.751

2.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.

Authors:  Ameya Gokhale; Thomas K Weldeghiorghis; Veena Taneja; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

3.  A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model.

Authors:  Seetharama D Satyanarayanajois; Barlas Büyüktimkin; Ameya Gokhale; Sharon Ronald; Teruna J Siahaan; John R Latendresse
Journal:  Chem Biol Drug Des       Date:  2010-06-23       Impact factor: 2.817

4.  [Alefacept. Successful long-term therapy of a severe psoriasis].

Authors:  J Schmitt; E Stoller; G Wozel
Journal:  Hautarzt       Date:  2005-04       Impact factor: 0.751

5.  Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice.

Authors:  Ameya Gokhale; Shanthi Kanthala; John Latendresse; Veena Taneja; Seetharama Satyanarayanajois
Journal:  Chem Biol Drug Des       Date:  2013-07       Impact factor: 2.817

6.  Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein Interaction.

Authors:  Rushikesh Sable; Thomas Durek; Veena Taneja; David J Craik; Sandeep Pallerla; Ted Gauthier; Seetharama Jois
Journal:  ACS Chem Biol       Date:  2016-07-01       Impact factor: 5.100

7.  Modulation of co-stimulatory signal from CD2-CD58 proteins by a grafted peptide.

Authors:  Pravin Parajuli; Rushikesh Sable; Leeza Shrestha; Achyut Dahal; Ted Gauthier; Veena Taneja; Seetharama Jois
Journal:  Chem Biol Drug Des       Date:  2020-10-02       Impact factor: 2.817

Review 8.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

9.  MDcons: Intermolecular contact maps as a tool to analyze the interface of protein complexes from molecular dynamics trajectories.

Authors:  Safwat Abdel-Azeim; Edrisse Chermak; Anna Vangone; Romina Oliva; Luigi Cavallo
Journal:  BMC Bioinformatics       Date:  2014-05-06       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.